A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
NCT06608901
Recruiting
This study is researching an experimental drug called REGN7544 (called "study drug"). The study is focused on adult patients (18 to 85 years) hospitalized due to a serious infection (called "sepsis") and receiving standard-of-care medications for low blood pressure (called "vasopressors") due to sepsis. The aim of the study is to see how safe, tolerable, and effective the study drug is by observing the effects on blood pressure and the total amount of vasopressor dose received during your stay... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
04/25/2025
Locations: Emory University Hospital, Atlanta, Georgia +1 locations
Conditions: Sepsis-Induced Hypotension
Register for Updates
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332
Recruiting
The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/25/2025
Locations: University of Utah, Salt Lake City, Utah +6 locations
Conditions: Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Register for Updates
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094
Recruiting
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (K... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +167 locations
Conditions: Colorectal Neoplasms
Register for Updates
Cardiovascular Risk Reduction for Adults With Food Insecurity Using Structured Incentives
NCT06818669
Recruiting
The overarching aim of this proposal is to test the efficacy and cost-effectiveness of CVD-FIT, a novel, multi-component intervention that includes three components: 1) monthly income supplementation; 2) weekly structured incentive for the purchase of healthy food options; and 3) evidence-based telephone delivered CVD risk reduction education and skills training in African Americans with food insecurity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University at Buffalo, Buffalo, New York
Conditions: Cardiovascular Diseases
Register for Updates
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404
Recruiting
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Omega Research Consultants, DeBary, Florida +73 locations
Conditions: Arthritis, Psoriatic
Register for Updates
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure: A Randomized Control Trial
NCT06957366
Recruiting
PAUSE 2 study is a prospective, open-label, blinded-endpoint non-inferiority RCT of PAUSE vs. ASRA management in DOAC treated high risk patients with AF/VTE who need elective high bleed risk surgery/procedure and/or any procedure involving neuraxial anesthesia. The purpose of the PAUSE 2 study is to show that PAUSE management will be as safe (i.e., non-inferior) as ASRA management, with 95% of patients having low/undetectable pre-operative DOAC levels \<30 ng/mL in each group., at the time of su... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Hartford Health Care, Hartford, Connecticut +13 locations
Conditions: Atrial Fibrillation (AF), VTE
Register for Updates
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
NCT02257866
Recruiting
Background: - Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people s genes and follow people over time to see how the disease affects them. Objective: - To learn the signs, symptoms, imaging tests, genetic markers, and blood tests that can help identify people with vasculitis and predict what will happen to them over t... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Takayasu's Arteritis, Giant Cell Arteritis, Polyarteritis Nodosa, Relapsing Polychondritis, ANCA-Associated Vasculitis
Register for Updates
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
NCT03147885
Recruiting
This phase Ib/II trial is aimed at studying the combination of a drug named Selinexor (selective inhibitor of nuclear export) in combination with standard therapy for B cell Non-Hodgkin's lymphoma called R-CHOP. The investigators will establish maximum tolerated dose of Selinexor in combination with RCHOP and also study the efficacy of this combination for therapy of B cell Non-Hodgkin's lymphoma. Giving Selinexor plus chemotherapy may work better in treating patients with B cell non-Hodgkin lym... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Extranodal Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Register for Updates
Dual Mobility Acetabular Cups in Revision TJA
NCT04090359
Recruiting
The aim of this study is to the compare clinical outcomes of patients undergoing a revision total hip arthroplasty (THA) with the use of a dual mobility bearing versus a single bearing design with the use of a large femoral head (36mm or 40mm). We hypothesize the use of dual-mobility components in revision THA will be associated with a lower dislocation rate in the first year following surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: New York University Medical Center, New York, New York +1 locations
Conditions: Dislocation, Hip
Register for Updates
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
NCT04472767
Recruiting
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Hepatocellular Carcinoma, HCC
Register for Updates
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
NCT04902443
Recruiting
Background: Less toxic and more effective treatments are needed for cancers caused by viruses. These cancers include Hodgkin and non-Hodgkin lymphoma, hepatocellular carcinoma, head and neck cancer, nasopharyngeal carcinoma, gastric cancer, anal cancer, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, Merkel cell carcinoma, Kaposi sarcoma, and leiomyosarcoma. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of pomalidomide plus nivolumab... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/25/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Viral Associated Malignancies, Kaposi Sarcoma, EBV/KSHV-associated Lymphomas
Register for Updates
A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
NCT05083182
Recruiting
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
Gender:
ALL
Ages:
Between 5 years and 17 years
Trial Updated:
04/25/2025
Locations: Childrens Hospital Los Angeles, Los Angeles, California +49 locations
Conditions: Arthritis, Juvenile
Register for Updates